Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, April 1st. Leerink Partnrs analyst D.

Leerink Partnrs also issued estimates for CRISPR Therapeutics’ Q2 2025 earnings at ($1.38) EPS, Q3 2025 earnings at ($1.39) EPS, Q4 2025 earnings at ($1.45) EPS, FY2025 earnings at ($5.58) EPS ...

A comprehensive examination of how financial experts perceive Regeneron Pharmaceuticals is ... Neutral | $759.00|$940.00 | |David Risinger |Leerink Partners |Raises |Outperform | $834.00|$762. ...

In a report released on March 2, David Risinger from Leerink Partners maintained a ... AnaptysBio, and Regeneron. According to TipRanks, Risinger has an average return of 10.3% and a 56.15% ...

Analysts at Leerink agreed with Sanofi that, despite falling short of statistical significance in the Phase II TIDE-Asthma trial, amlitelimab warrants further development in this indication.

Leerink Partners analyst Puneet Souda maintained a Hold rating on CryoPort (CYRX – Research Report) yesterday and set a price target of $10.00. The company’s shares closed yesterday at $5.55 ...

Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent. “With this FDA decision, Dupixent is now approved for seven ...

Leerink lowered the firm’s price target on AirSculpt Technologies (AIRS) to $2.50 from $6.50 and keeps a Market Perform rating on the shares. Q4 results featured a continuation of challenges ...

TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...